About us Career Contact us




GIBH Profile

Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (abbreviated as “GIBH”) is the result of joint effects of Chinese Academy of Sciences, the People’s Government of Guangdong Province and the People’s Government of Guangzhou Municipality. It is officially approved by the Central Institutional Organization Commission in March 2006 and is the first research institute that is under the joint management of CAS and local government. Currently, GIBH is engaged in research areas including stem cell and regenerative medicine, chemical biology, immunology and infectious diseases, public health, and the development of novel scientific equipment.


Aimed to achieve the goal of "Healthy China" strategy and satisfy human health demands, GIBH is exploring disease mechanism with the cutting-edge technologies and developing innovative protocols for disease control and prevention. It provides excellent R&D platform in biomedicine and functions as an incubator for bioengineering and pharmaceutical industries to support local economic development as well as national strategic science and technology programs.


GIBH currently consists of four core research unitsSouth China Institute of Stem Cell and Regenerative Medicine, Institute of Chemical Biology, Center for Infection and Immunity and Institute for Public Healthand a Drug Discovery Pipeline Core Transformation Unit. It provides state-of-the-art core facility and animal center, as well as Centers for Information Supercomputing. GIBH has established several key laboratories including CAS Regenerative Medicine Key Laboratory, Guangdong Province Stem Cell and Regenerative Medicine Key Laboratory and Guangdong Province Biomedical Computing Key Laboratory. Together with Guangzhou Respiratory Disease Institute, a joint Respiratory Disease National Key Laboratory has been established. These research units are the cornerstones for the coming Guangzhou Regenerative Medicine and Health Guangdong Laboratory.


GIBH recruits employees and graduate students worldwide. Currently, it has 381 employees and 304 graduate students and 82.7% of them are aged under 35. In addition, GIBH has recruited 35 senior scientists and most of them are trained overseas (including 6 non-Chinese scientists). They have received many honorary titles including two winners of the National Natural Fund for Distinguished Young Scholars, one member of the National Key Research and Development Program Expert, six chief scientists of National Key Research and Development Program, one Youth Science and Technology Innovation Leader, four winners of the National Excellent Young Scientist Fund, one Yangtze River scholar, one young Yangtze River scholar, 18 winners of the CAS Hundred Talents Program, one CAS Outstanding Young Scientist, six Specially-appointed Researchers of the CAS, four Extraordinary Young Scientists of CAS, three South Guangdong Hundred Talents, four winners of the Guangdong Province Excellent Youth, four winners of the Guangdong Province Leading Talent and one winner of the Guangdong Province Innovation Group Award.


Researches in GIBH are funded by National Natural Science Foundation, CAS, Guangdong Province and Guangzhou municipal government, including six national major research plan projects, four national key R&D plan project, one CAS Strategic Priority Research Program (class A), one national major scientific research device and equipment development project, and one National Natural Science Foundation Innovative Study. Researches in GIBH have resulted in more than 1200 peer-reviewed scientific papers and won many prestigious awards including National Natural Science Award Second Prize, the Achievements of Outstanding Science and Technology China Academy Award, Southern Guangdong Special Contribution Award and Southern Guangdong Innovation Award, Guangdong Province Science and Technology Award First Prize (three times) and Guangzhou Science and Technology Award First Prize (three times).


GIBH provides Ph.D. programs in Biology, Basic Medicine and Medicinal Chemistry and master programs in Chemical Engineering and Bioengineering. In addition, GIBH has collaborative educational programs with China University of Science and Technology, Jilin University, Anhui Universities, South China University of Technology, Guangzhou Medical University etc.. Moreover, GIBH provides academic training for international students at master or Ph.D. level and has accepted applicants from Spain, Germany, Russia, India etc..


GIBH is committed to promote local industry development with innovative technology and competitive intellectual property. As of December 2017it has filed 550 patent applications, among which 430 are domestic patents, 74 are international patents and 46 are PCTs. A total of 237 patents are authorized (212 authorized domestic patents and 15 authorized international patents). The patent "A Construction Method of Immunodeficient Mice Model" won the 19th National Outstanding Innovation Award and the 4th Guangdong Outstanding Innovation Award. The anti-Alzheimer's Disease Class 1.1 candidate drug GIBH130, the anti-leukemia Class 1.1 drug GZD824 and the anti-neoplastic Class 1 new drug ASK120067 have been approved by CFDA for clinical trials. GIBH received the title of "Guangdong New R&D Institute" in 2015.


GIBH highly values international cooperation and has established cooperation with Max Planck Society, University of Auckland, University of Hong Kong and Chinese University of Hong Kong. The Max Plank-GIBH Research Center is the first international research center of Max Plank Society in China and the GIBH-Hong Kong Center is the first registered entity of science and technology in Hong Kong on behalf of CAS. GIBH has successfully hosted "Guangzhou International Stem Cell and Regenerative Medicine Forum” for ten consecutive years, which invited many world famous stem cell researchers including Nobel Laureates and promotes regenerative medicine research in South China.


GIBH will follow the guidance of Socialism with Chinese Characteristics in the New Era proposed by General Secretary Xi Jinping to earnestly implement the "First Mover" plan of the CAS and deeply implement the "One-Three-Five" planning; it will take the construction of the International Scientific Innovation Center in the Guangdong-Hong Kong-Macau Greater Bay Area and Guangdong Provincial Laboratory as the opportunity to give full play to the strength of national strategic technologies and continue to make contributions to the national strategy of "Healthy China". 



Message From The Director 

Stay True to The Mission, and Forge Ahead 

Spring returns to the earth and everything looks fresh! At the occasion of bidding farewell to the old and ushering in the new, on behalf of the leadership, I give my sincere greetings to the staffs, students, retirees and all leaders and friends of people from all social circles that care for and support the development of CAS GIBH! 

In 2016, all efforts are not made for nothing. 

At the outset of "Thirteenth Five-Year" Plan', under the leadership of CAS, Guangdong Province and Guangzhou City, GIBH closely focused on the "One-Three-Five" strategic plan with the joint effort of all employees and students and in the principle of "taking the lead in action" and dared to innovate and make plans while being down-to-earth and being brave enough to struggle, and finally achieved considerable progress in the careers. 

During the past year, we made joint efforts to innovate and achieved new progress in scientific research and result transformation. We obtained a batch of national key R&D plan chief projects and was granted the National Natural Science Foundation excellent young science funded projects for consecutive three years; after ten years’ self-development, the “anti-Alzheimer’s disease” class 1.1 new drug obtained the clinical approval; Guangdong Province Regenerative Medicine and Health Laboratory was listed into the first batch of Guangdong Province laboratory construction plan. We are delighted to see that, our young scientific research personnel have become the backbone for GIBH’s science and technology innovation. 

During the past year, we rose abruptly based on its accumulated strength and marched towards a bright future through international cooperation and platform construction. GIBH’s Hong Kong Center and Guangzhou - Hong Kong Stem Cell and Regenerative Medicine Center (Hong Kong) settled in Hong Kong Science Park; the Regeneration Medicine Joint Research Center (Max Plank -GIBH) jointly initiated by GIBH and Max Plank was officially established, which is the first international research center established by Max Plank in China; the construction of the postgraduate apartment with an area of building of 25000 square meters was finished, and all the students settled in smoothly; the decoration of the clinical therapeutic stem cell preparation GMP platform was also completed. We deeply feel that, even the smallest entity has its own brand; even the smallest research unit has huge energy. 

In 2017, just as jade needs to be polished, one needs to go through trials and tribulations to be strong. 

As a Chinese saying goes, a wise man changes as time and event change. Currently, the world is at the stage of the most active innovation, China ushers in the opportunity to climb the peak of world’s science and technology, and GIBH will be faced with new opportunities and challenges. It is worth mentioning that innovation is the gene of our establishment and development and is the source of our future development. No matter whatever the difficulties lie ahead, we can still break open a way through brambles and thorns and march towards with chest out. 

We obtain knowledge by investigation of things through the stimulating influence of a good teacher. In the new year, we will actively respond to President Xi’s call of rolling up our sleeves to work harder in his 2017 New Year’s greetings. Stay true to the mission, and forge ahead. Dare to assume responsibilities and dare to innovate! The officer may not be without breadth of mind and vigorous endurance. 

I wish a happy new year, a good health, happiness at home and everything well to all teachers, students, employees and their family, and friends! Wish we will have a brighter future! 


Duanqing Pei 

Jan. 2017 



By enhancing its capability of local innovation and competency in the field of biomedicine and health, GIBH aims to be a R&D centre specializing in the core technology of pathogenic mechanisms and biomedical and chemical sciences; a platform contributing to the improvement of global biomedicine and relevant industries; a base attracting and cultivating leading talents in international science frontier; and a window in South China for bringing in international cooperation in the field of biomedicine.


Driven by the demands of the Chinese national health and the development of biomedicine, GIBH is dedicated to focusing on leading research in pathogenic mechanisms, technological innovation, and high level integration. Additionally, GIBH seeks to enhance its capability of R&D and commercialization in the fields of biomedicine, vaccines and diagnose in order to promote the development of Chinese and global standard of health care and medicine.

Major Areas of Research Expertise  

Stem Cell and Regenerative Medicine, Chemical Biology, Infection and Immunity.











The Public Instrument Center  

The center accommodates most of GIBH’s instruments, worth a total of 55 million RMB. Instruments include Flow Cytometer, Laser Scanning Confocal Microscope, High Content Screening System, DNA/RNA Synthesizer, Peptide Synthesizer, Biomolecular Interaction Analysis, X-ray Diffractometer, 400MHz and 500MHz Nuclear Magnetic Resonance Spectrometer, Liquid Chromatogram-Mass spectrometry, Gas Chromatography-Mass Spectrometer, high performance centrifugal machines, and PCR Amplifiers. The center opens its service externally after the internal demands are met.

The total value of the instruments at GIBH is worth 110 million RMB, among which there are 91 instruments valued at over 200,000 RMB.


The laboratory Animal Centre  

The centre aims to build a leading platform of laboratory animals by observing the stringent quality control and standard operating procedures in order to perform high quality animal experiments. The center covers an area of 4,400 square meters and provides GIBH research teams with standardized animals, reliable facilities which assist research teams to complete related experiments.

The centre, which is run entirely by ALLAC standards, goes for ALLAC verification and has obtained the certification of qualified laboratory animal facilities and the license for using laboratory animal issued by Guangdong Laboratory Animal monitoring Institute. Recently, the centre has become the largest standard laboratory animal centre in Guangdong Province which has established stable collaborating relationships with the Guangdong Laboratory Animal Monitoring Institute, Shanghai Laboratory Animal Centre of Chinese Academy of Sciences, and many colleges and universities in the Guangdong area.


Copyright ©2002-2008 Guangzhou Institutes of Biomedicine and Health,Chinese Academy of Sciences